Pharma Mar SA
MAD:PHM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.24
80.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pharma Mar SA
Pharma Mar SA
Interest Income Expense
Pharma Mar SA
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharma Mar SA
MAD:PHM
|
Interest Income Expense
-€490k
|
CAGR 3-Years
43%
|
CAGR 5-Years
34%
|
CAGR 10-Years
21%
|
|
|
Grifols SA
MAD:GRF
|
Interest Income Expense
-€332.3m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Oryzon Genomics SA
MAD:ORY
|
Interest Income Expense
-€1.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Biotechnology Assets SA
MAD:BST
|
Interest Income Expense
-€314.8k
|
CAGR 3-Years
21%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Pharma Mar SA
Glance View
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 477 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.
See Also
What is Pharma Mar SA's Interest Income Expense?
Interest Income Expense
-490k
EUR
Based on the financial report for Sep 30, 2024, Pharma Mar SA's Interest Income Expense amounts to -490k EUR.
What is Pharma Mar SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
21%
Over the last year, the Interest Income Expense growth was 89%. The average annual Interest Income Expense growth rates for Pharma Mar SA have been 43% over the past three years , 34% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet
